The synergistic effect of combining TKIs and ICIs, attributed to VEGF signaling inhibition and tumor immune microenvironment transformation, has been supported by clinical trials demonstrating superior efficacy for advanced HCC as a first‐line treatment [12, 26, 27, 28]. Here, VEGFA is linked to hepatocellular carcinoma.